A Phase I Study of HW201877 in Healthy Subjects
Recruiting now · Phase 1 · Has a placebo group
Conditions studied: Healthy Participants, IBD (Inflammatory Bowel Disease)
In brief
This is a Phase I, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and food effect (FE) of HW201877 in healthy subjects following (1) a single ascending dose (Part 1), which includes a single-dose, two-period crossover FE cohort; (2) a multiple ascending dose (Part 2).
Key facts
- Study ID
- NCT07373457
- Run by
- Wuhan Humanwell Innovative Drug Research and Development Center Limited Company
- People needed
- 104
- Starts
- 2025-06-26
- Expected to finish
- 2026-03-01
- Last updated by the study team
- 2026-01-28
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- The First Hospital of Jilin University — Changchun, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.